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Abstract: Microscopic colitis (MC) often debuts around or after menopause and is divided into lymphocytic- and collagenous colitis. 
The aim of this study was to examine whether factors influencing sex hormone levels differed between subgroups of MC as well as 
between patients and controls. A self-administered questionnaire about parity was completed which included questions surrounding age 
at first childbirth, menarche and menopause, the use of oral contraceptives, and hormonal replacement therapy. Patients with lympho-
cytic colitis had children less often compared to those with collagenous colitis (OR = 0.20, 95% CI = 0.05–0.86), however no differences 
were observed between patients with persistent or transient disease. Patients were less often older than 15 years of age at menarche 
(OR = 0.48, 95% CI = 0.26–0.91) and were younger at menopause (OR = 0.30, 95% CI = 0.16–0.56) compared with controls. Thus, no 
obvious association between factors influencing sex hormone levels and presence of MC could be found.
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Introduction
Microscopic  colitis  (MC)  is  a  chronic  disease 
of  unknown  etiology  with  mucosal,  colonic 
  inflammation. The disease is divided into collagenous 
colitis (CC) and lymphocytic colitis (LC), depending 
on the histopathological picture.1 Interestingly, MC 
often debuts in women of mid- or upper middle age, 
at the time when endogenous sex hormone levels are 
diminished.2 Thus, the involvement of sex hormones 
as well as autoimmunity has been discussed in the 
pathophysiology of MC.2 Sex hormones may influ-
ence the function of the gastrointestinal tract. Both 
estrogens  and  progesterone  have  been  shown  to 
reduce the inflammation in experimentally induced 
colitis in rats.3,4 Estrogens exhibit anti-inflammatory 
and epithelial barrier-enhancing properties in colitic 
rats, and the protective effect of a fermented soy germ 
extract are based on protease inhibition and is partly 
mediated by activity of an estrogen receptor ligand.5 
The assumption among health care professionals is, 
therefore, that the fall of estrogen- and   progesterone 
levels at menopause could predispose to the debut of 
a colonic inflammation, triggered by luminal   factors. 
However,  associations  between  factors  influenc-
ing  sex  hormone  levels  and  MC  have  never  been 
examined.
The aim of the present study was to compare par-
ity age at first childbirth, menarche and menopause, 
as well as the use of oral contraceptives (OC) and 
hormonal replacement therapy (HRT)—factors that 
may affect the level of sex hormones during life time 
—between subgroups of patients suffering from MC 
and between patients and a population-based control 
group.
Material and Methods
Patients
Women who had been treated for MC at any outpatient 
clinic of the Departments of Gastroenterology, Skåne, 
between  2002  and  2010,  were  identified  through  a 
search for the ICD-10 classification for the two forms 
CC and LC (K52.8) in outpatient records, as well as 
in the local register at the Department of Pathology, 
Skåne University Hospital, Malmö. About one-third of 
the total number of patients identified were excluded 
as they were over 73 years of age, since they had many 
other concomitant diseases and drug therapies, repre-
senting secondary MC.6 Of the patients recognized, 
only the 240 patients (median age 63 years, range 
22–73 years) who had the diagnoses verified by his-
topathological examination of colonic biopsies were 
invited to participate in the present study. Altogether, 
159 (median age 63 years, range 22–73 years) of the 
240 patients invited accepted to participate and were 
enrolled in the study. One patient was excluded due to 
another  inflammatory  bowel  disease  (IBD)  diagno-
sis a few weeks after inclusion, leaving 158 patients 
(66%), and of these, 133 also agreed to provide blood 
  samples.  These  patients  represent  the  majority  of 
female cases of diagnosed MC in the southernmost 
districts of   Sweden under the age of 73 years.
Controls
The Malmö Diet and Cancer Study (MDCS)
The  Malmö  Diet  and  Cancer  Study  (MDCS),  a 
  population-based  prospective  cohort  study,  invited 
all  women  in  Malmö  born  between  1923  and 
1950  to    participate.  Recruitment  was  carried  out 
between 1991 and 1996, and 41% of eligible sub-
jects   participated. In all, 17,035 women completed 
the  baseline    examination.7  The  MDCS  baseline 
examination  included  a  dietary  assessment,  a  self-
  administered  questionnaire  about  marital  status, 
  education, employment, smoking- and alcohol habits, 
parity, age at first childbirth, menarche, and meno-
pause, exposure to OC (ever/never), current use of 
HRT (yes/no), and medical conditions and medica-
tion, as well as anthropometric measurements and the 
collection of blood samples.8 Menopausal status was 
defined using information on previous surgery and 
menstrual status. The classification of pre-, peri- and 
postmenopausal women has been described in detail 
elsewhere.9 Women selected as controls in a previous 
study on breast cancer were used in the present study 
as controls. In all, 737 subjects (median age 56 years, 
range 45–73 years) were available, the only exclusion 
criterion was that they should not have had a previous 
breast cancer at baseline.10
Patient recruitment and study design
Between March and June 2011, invitations includ-
ing information about the study and the questionnaire 
described above were sent by mail to all 240 women 
identified with MC. They were also invited to visit 
the outpatient clinics of the Departments of Gastro-
enterology, Skåne University Hospital, Malmö or the MC and hormonal factors
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Central  Hospital  in  Kristianstad,  to  provide  blood 
samples. A reminder letter was sent out a month after 
the invitation letter to those who had not answered. 
  Questionnaires  were  completed  1–3  weeks  before 
blood samples were collected. Medical records were 
scrutinized, and age, gastrointestinal symptoms, exam-
inations, and treatments were recorded. The diagnosis 
of either CC or LC was registered and patients were 
divided into two groups based on their clinical pre-
sentation of MC. One group included patients with 
at least two episodes of watery diarrhea, and/or their 
dependence  on  long-term  treatment  of  corticoster-
oids to maintain remission and/or two pathological 
intestinal mucosa biopsies (MC1, n = 78, in the final 
population for statistical calculation). These criteria 
are in line with the consensus for diagnosing IBD.11 
The other group included patients who had had only 
one episode of severe diarrhea or had had a normal 
biopsy after the initial pathological intestinal biopsy, 
in combination with clinical remission (MC2, n = 53, 
in  the  final  population  for  statistical  calculation). 
Patients with concomitant celiac disease (9 patients) 
or an acute gastroenteritis briefly prior to the diag-
nostic colonoscopy (4 patients) were excluded as they 
had an obvious organic explanation for the intestinal 
inflammation, and were considered to be suffering 
from secondary MC.6 Concomitant diseases and drug 
treatment in the controls and the patient population 
have been described previously.12 In addition to MC, 
the patient group also suffered from many other dis-
eases, where hypertension (36%), rheumatoid arthri-
tis (24%), and asthma (17%) were the most prevalent. 
These diseases were more prevalent in the MC group 
than in the controls.12
Patients  were  compared  to  controls  from  the 
MDSC study.
Statistical analyses
The data were analyzed using the statistical software 
package SPSS for Windows© (Release 20.0; IBM, 
NY, USA). The patients were significantly older, with 
a wider age range than the controls. Therefore, the 
12 patients younger and the two patients older than the 
controls were excluded, as were patients with celiac 
disease and gastroenteritis (13 patients), leaving 131 
of the original 158 patients for statistical analysis of 
patients compared to controls. Thus, both controls 
and patients were within the age range 45–73 years. 
First, the distribution of continuous variables (age, 
disease duration, and body mass index (BMI)) was 
tested  using  a  one-sample  Kolmogorov-Smirnov 
test.  All  these  distributions  differed  significantly 
(P , 0.05) from a normal   distribution. Therefore, 
the factors studied were categorized and the values 
were  given  as  median    (interquartile  range). There 
were missing values in some variables, which were 
given a category of their own.   Differences between 
groups were calculated by the 2-tailed Mann-Whitney 
U-test. Fisher’s exact test was used for categorical 
variables. A P-value , 0.05 was considered statisti-
cally significant.
Age was divided into 5-year intervals. Smoking 
was divided into three categories: subjects who had 
never smoked, subjects who had stopped smoking, 
and current smokers, including both regular and occa-
sional smokers. Subjects who denied intake of beer, 
wine, and alcoholic liquids during the previous year 
were defined as having no alcohol intake. Subjects 
were divided into three groups: subjects consuming 
no  alcohol,  subjects  who  had  drunk  some  alcohol 
in the previous year, but not in the past month, and 
subjects who had drunk some alcohol in the previous 
month. Employment was divided into three catego-
ries: employed, retired, or other, where other included 
housewives, students, and the unemployed. Education 
was divided into having a university education or not.
Parity was dichotomized as nulliparous and parous 
in  order  to  yield  larger  groups. Age  at  first  child-
birth  was  also  dichotomized  as  #25  years  of  age 
and .25 years of age. HRT was defined as non-use, 
and use of either estrogen or progesterone replace-
ment  therapy,  or  combined  estrogen  and  proges-
terone  therapy. Age  at  menopause  was  categorized 
as #45 years, .45 and ,53 years, and $53 years. 
These classifications were in accordance with previ-
ous classifications.13 The first category was used as 
reference. Factors intended to be studied   (independent 
variables),  namely,  age  at  menarche,  first  child-
birth, and menopause; parity; exposure to OC (ever/
never);  exposure  to  HRT    (current/none);  or  bilat-
eral oophorectomy (yes/no), were initially examined 
using an unconditional logistic regression to calculate 
odds ratios with 95% confidence intervals (OR with 
95% CI). Analyses were adjusted in a second model 
for age at baseline, smoking- and alcohol habits, level 
of education, and employment, as these   characteristics roth et al
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differed  by  .5  percentage  between  controls  and 
patients, and between MC1 and MC2. Analyses were 
also adjusted for age at baseline, smoking- and alcohol 
habits, employment, and civil status in the calculations 
between CC and LC.   Calculations were first performed 
on the whole patient group compared with controls, 
and then separately for patients with CC compared to 
patients with LC, and patients with MC1 compared to 
patients with MC2 (dependent variables).
ethical considerations
The Ethics Committee of Lund University approved 
the study protocol for patients (Dnr 2009/565 and 
2011/209) and controls (Dnr 51-90). All participants 
gave their written, informed consent to take part in 
the study.
Results
Patient characteristics
In total, 131 women (median age 63 (59–67) years) 
with MC were included in the statistical calculations; 
CC was diagnosed in 82 patients (62.6%) and LC in 
49 patients (37.4%) (Table 1). Although identical in 
age range, the median age was higher in the patient 
group (P , 0.001). The duration of the disease was 
7 (3–14) years. Measurements of hemoglobin (Hb) in 
blood and C-reactive protein (CRP) in plasma were 
in the majority of patients within reference values, 
showing that the patients were in an overall inac-
tive phase (data not shown). Of the patients, 91.7% 
were born in Sweden compared with 90.2% of the 
  controls. The number of married patients did not dif-
fer between CC and LC (P = 0.362). As patients with 
Table 1. Patient and control characteristics.
controls  
n = 737
Microscopic colitis  
n = 131
P-value cc  
n = 82
Lc  
n = 49
P-value
Age at study (years) 56.16  
(50.47–62.36)
63.00  
(58.94–67.15)
0.000 62.77  
(58.94–67.30)
63.78  
(58.74–66.85)
0.761
Age groups (%) 0.000 0.763
  45–49 17.1 4.6 4.9 4.1
  50–54 22.3 6.9 4.9 10.2
  55–59 22.3 13.7 15.9 10.2
  60–64 19.5 32.1 34.1 28.6
  65–69 11.7 26.0 24.4 28.6
  70–74 7.2 16.8 15.9 18.4
Smoking habits (%) 0.076 0.380
  Never smoked 42.3 27.5 26.8 28.6
  Former smokers 29.9 36.6 32.9 42.9
  Current smokers 27.8 35.9 40.2 28.6
Alcohol habits (%)
  Missing value 0.3 3.8 0.206 6.1 0 0.573
  Nothing last year 11.0 16.0 13.4 20.4
    Something last year  
(not last month)
12.3 13.0 13.4 12.2
  Something last month 76.4 67.2 67.1 67.3
BMI (kg/m2) 24.84  
(22.55–27.79)
24.88  
(22.62–29.15)
0.451 24.70  
(21.85–29.49)
24.90  
(23.10–28.33)
0.977
  Missing value (%) 0 44.3 40.2 51.0
Married women (%) 61.9 58.0 0.542 61.0 53.1 0.362
Level of education (%)
  Missing value 0 2.3 0.002 3.7 0 0.578
  #12 years at school 76.1 67.9 67.1 69.4
  .12 years at school 23.9 29.8 29.3 30.6
employment (%) 0.001 0.567
  employed 65.7 44.3 46.3 40.8
  retired 26.5 49.6 46.3 55.1
  Others* 7.9 6.1 7.3 4.1
notes: *Includes housewives, students, and unemployed. Values are given as median (interquartile range). Mann-Whitney U-test or Fischer’s exact test 
were used for statistical calculations. P , 0.05 was considered statistically significant.MC and hormonal factors
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LC increased in age, the number of retired persons 
was greater, but these changes did not reach statistical 
significance (P = 0.763 and P = 0.567, respectively). 
There was no difference between CC and LC whether 
MC was persistent or transient (P = 0.273).
Smoking and drinking habits
More patients than controls were former or current 
smokers (Table 1). There was no statistically signifi-
cant difference between CC and LC, or between MC1 
and  MC2,  concerning  smoking  habits  (P  =  0.380 
and P = 0.128, respectively). There were only a few 
patients and controls who consumed beer and stron-
ger  alcoholic  beverages.  Thus,  the  alcohol  intake 
  consisted mainly of wine. The majority of subjects 
who drank imbibed 1–2 glasses a day. Only a minority 
of the subjects were non-users of alcohol (Table 1).
reproductive factors
The only difference between CC and LC was that 
among patients with LC, where there was a higher per-
centage of nulliparity (Table 2). Furthermore, patients 
with LC had fewer children than patients with CC (2 
(1–2) and 2 (1–3), respectively), although this did 
not reach statistical significance (P = 0.057). There 
was no difference in reproductive factors influencing 
sex hormone levels between those patients who had a 
transient MC and those with persistent MC (Table 3). 
Table 2. Differences between collagenous colitis (CC) and lymphocytic colitis (LC).
cc  
n = 82  
%
Lc  
n = 49  
%
cc/Lc
crude OR, 95% cI OR, 95% cI
Age at menarche (year)
Missing value 9.8 6.1 “–” “–”
#12 (reference) 28.0 18.4 1.00 1.00
.12 to ,15 47.6 51.0 1.64 (0.65–4.11) 1.68 (0.62–4.54)
$ 15 14.6 24.5 2.56 (0.84–7.76) 3.42 (0.96–12.14)
parity
Missing value 3.7 2.0 “–” “–”
Nullipara (reference) 4.9 16.3 1.00 1.00
Parous 91.5 81.6 0.27 (0.08–0.94) 0.20 (0.05–0.86)
Age at first childbirth (year)
Missing value 4.9 2.0 “–” “–”
Nullipara (reference) 4.9 16.3 1.00 1.00
#25 62.2 61.2 0.29 (0.08–1.06) 0.22 (0.05–0.98)
.25 28.0 20.4 0.22 (0.05–0.89) 0.16 (0.03–0.79)
Age at menopause (year)
Missing value* 25.6 16.3 “–” “–”
#45 (reference) 22.0 18.4 1.00 1.00
.45 to ,53 28.0 40.8 1.74 (0.64–4.73) 1.92 (0.64–5.81)
$ 53 24.4 24.5 1.20 (0.41–3.51) 1.09 (0.33–3.64)
exposure to Oc
Missing value 2.4 0 “–” “–”
Never (reference) 23.2 24.5 1.00 1.00
ever 74.4 75.5 0.96 (0.42–2.20) 0.97 (0.40–2.37)
exposure to HRT
Missing value 0 0 “–” “–”
Non (reference) 91.5 91.8 1.00 1.00
Current 8.5 8.2 0.95 (0.26–3.44) 0.91 (0.23–3.59)
Bilateral oophorectomy
Missing value 7.3 8.2 “–” “–”
No (reference) 79.3 71.4 1.00 1.00
Yes 13.4 20.4 1.69 (0.65–4.36) 1.68 (0.58–4.88)
notes: *Missing values includes missing values and premenopausal women. Calculations were adjusted for age, smoking habits, alcohol habits, civil 
status, and employment.
Abbreviations: hrT, hormonal replacement therapy; CI, Confidence interval; OC, oral contraceptives; Or, Odds ratio.roth et al
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More of the patients had their menarche before the 
age of 15 years. Many controls reached menopause 
between 45–53 years of age, whereas more patients 
with  MC  were  younger  than  45  years  when  they 
reached menopause (Table 4). There was no differ-
ence in parity or age at first childbirth between the 
groups (Table 4). The majority of MC patients had 
used OC at some period of their life. In contrast, fewer 
patients than controls were on current treatment with 
HRT (Table 4).
Discussion
The present study showed no differences in the influ-
ence of sex hormones between the subgroups, except 
that patients with LC were more often nulliparous 
than patients with CC. This is interesting as some 
studies have shown a female predominance in both 
CC and LC,2 whereas others have not been able to 
confirm  this  in  LC.14,15  Patients  with  MC  differed 
from the external control group as they had reached 
menarche and menopause earlier, but there was no 
difference in parity or age at first childbirth. More of 
the patients than controls had been exposed to OC at 
any time during their lives, and fewer were exposed 
to current HRT.
Although the debut of MC often occurs in pre-
dominantly middle-aged women, the role of sex hor-
mones has never been examined in this entity. MC is 
Table 3. Differences between persistent (MC1) and transient (MC2) microscopic colitis.
Mc1 
n = 78 
%
Mc2 
n = 53 
%
Mc1/Mc2
crude OR 95% cI OR 95% cI
Age at menarche (year)
Missing value 10.3 5.7 “–” “–”
#12 (reference) 24.4 24.5 1.00 1.00
.12 to ,15 47.4 50.9 0.94 (0.40–2.22) 0.94 (0.37–2.37)
$15 17.9 18.9 0.96 (0.33–2.81) 0.94 (0.29–3.04)
Age at first childbirth (year)
Missing value 3.8 3.8 “–” “–”
Nullipara (reference) 10.3 7.5 1.00 1.00
#25 64.1 58.6 0.81 (0.22–2.90) 1.40 (0.33–5.97)
.25 21.8 30.2 0.53 (0.13–2.11) 0.67 (0.15–3.05)
parity
Missing value 3.8 1.9 “–” “–”
Nullipara (reference) 10.3 7.5 1.00 1.00
Parous 85.9 90.6 0.70 (0.20–2.45) 1.03 (0.26–4.14)
Age at menopause (year)
Missing value* 23.1 20.8 “–” “–”
#45 (reference) 19.2 22.6 1.00 1.00
.45 to ,53 34.6 30.2 1.35 (0.51–3.59) 1.50 (0.52–4.30)
$53 23.1 26.4 1.03 (0.37–2.88) 1.42 (0.45–4.42)
exposure to Oc
Missing value 2.6 0 “–” “–”
Never (reference) 19.2 30.2 1.00 1.00
ever 78.2 69.8 1.76 (0.78–3.97) 2.24 (0.91–5.55)
exposure to HRT
Missing value 0 0 “–” “–”
Non (reference) 88.5 96.2 1.00 1.00
Current 11.5 3.8 3.33 (0.69–16.06) 3.48 (0.68–17.73)
Bilateral oophorectomy
Missing value 7.7 7.5 “–” “–”
No (reference) 17.9 13.2 1.00 1.00
Yes 74.4 79.2 1.45 (0.54–3.90) 1.43 (0.49–4.15)
notes: *Missing values includes missing values and premenopausal women. Calculations were adjusted for age, smoking habits, alcohol habits, level of 
education, and employment.
Abbreviations: hrT, hormonal replacement therapy; CI, Confidence interval; OC, oral contraceptives; Or, Odds ratio.MC and hormonal factors
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Table 4. Differences between controls and patients with microscopic colitis (MC).
controls 
n = 737 
%
Mc 
n = 131 
%
controls/microscopic colitis
crude OR, 95% cI OR, 95% cI
Age at menarche (year)
Missing value 0 8.4 “–” “–”
#12 (reference) 19.1 24.4 1.00 1.00
.12 to ,15 54.3 48.9 0.70 (0.44–1.12) 0.65 (0.38–1.09)
$15 26.1 18.3 0.55 (0.31–0.98) 0.48 (0.26–0.91)
parity
Missing value 2.6 3.1 “–” “–”
Nullipara (reference) 11.4 9.2 1.00 1.00
Parous 86.0 87.8 1.27 (0.67–2.40) 1.21 (0.61–2.40)
Age at first childbirth (year)
Missing value 2.6 3.8 “–” “–”
Nullipara (reference) 11.1 9.2 1.00 1.00
#25 53.6 61.8 1.40 (0.73–2.69) 1.46 (0.72–2.96)
.25 32.4 25.2 0.94 (0.46–1.91) 0.79 (0.37–1.69)
Age at menopause (year)
Missing value* 32.8 22.1 “–” “–”
#45 (reference) 11.0 20.6 1.00 1.00
.45 to ,53 39.9 32.8 0.44 (0.26–0.75) 0.30 (0.16–0.56)
$53 16.0 24.4 0.81 (0.45–1.46) 0.53 (0.28–1.03)
exposure to Oc
Missing value 0 1.5 “–” “–”
Never (reference) 50.2 23.7 1.00 1.00
ever 49.8 74.8 3.19 (2.08–4.89) 7.49 (4.46–12.43)
exposure to HRT
Missing value 0.4 0 “–” “–”
Non (reference) 79.5 91.6 1.00 1.00
Current 20.1 8.4 0.36 (0.19–0.69) 0.42 (0.22–00.83)
Bilateral oophorectomy
Missing value 66.5 7.6 “–” “–”
No (reference) 29.0 76.3 1.00 1.00
Yes 4.2 16.0 1.45 (0.79–2.65) 1.19 (0.60–2.35)
notes: *Missing values includes missing values and premenopausal women. Calculations were adjusted for age, smoking habits, alcohol habits, level of 
education, and employment.
Abbreviations: hrT, hormonal replacement therapy; CI, Confidence interval; OC, oral contraceptives; Or, Odds ratio.
sometimes characterized as a subgroup of IBD,16 and 
autoimmunity is assumed to be involved in the patho-
genesis of IBD.2 Autoimmune diseases are often in 
remission during pregnancy, since the elevated estro-
gen levels during pregnancy influence the cytokine 
profile in general, not only the cytokine profile in 
the gut.17 Prior studies on hormonal influences have 
been  performed  in  patients  with  IBD,  and  studies 
have shown an association between OC and a risk 
to develop IBD, especially Crohn’s disease, among 
younger, premenopausal women. This increased risk 
of IBD reverts to that of the non-exposed population 
when the women stop the use of OC.18 In a large pro-
spective study, postmenopausal hormone therapy was 
associated with an increased risk of ulcerative colitis 
(UC), but not Crohn’s disease.19 When scrutinizing all 
papers written about colonic toxicity of administered 
drugs and chemicals, a hypercoagulable state with 
ischemic colitis due to mesenteric vein thrombosis 
was the only association found between OC and the 
gastrointestinal  tract.20  Both  estrogen-  and  proges-
terone receptors are expressed in the gastrointestinal 
tract under normal conditions,21,22 with predominance 
of estrogen receptor β in the colon, mainly located 
in epithelial cells.21 Sex steroids have been shown to 
influence colonic transit time,23 chloride ion secre-
tion,24  and  epithelium  formation.25  One  important 
function of the intestinal epithelium is to provide a roth et al
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protective barrier for the internal milieu against lumi-
nal factors. The physical barrier is dependent on inter-
cellular tight junctions sealing the intercellular spaces 
between the epithelial cells.26 Increased intercellular 
permeability  has  been  implicated  in  the  pathogen-
esis of chronic, mucosal inflammation.27,28 There is 
a  physiological  link  between  circulating  estrogens 
and  estrogen  receptor β-mediated increase in  tight 
junction proteins, with pivotal functions in the main-
tenance of intercellular spaces in female rats.29 The 
protective role of estradiol in decreasing paracellular 
permeability enhances its beneficial effects on intesti-
nal barrier function.4 In recent years, progesterone has 
been reported to suppress inflammatory responses to 
reduce lipid peroxidation and cell membrane damage 
due to free oxygen radicals in clinical- and experi-
mental studies.3 Although sex hormones strenghten 
the epithelial barrier in experimental trials in rats,4,29 
pharmacological levels of estrogens and progesterone 
in OC and HRT taken over a long time span seem to 
increase the risk of IBD.18,19
Severe  MC  has  to  be  treated  by  a  derivation  of 
fecals  from  the  colonic  mucosa,  which  heals  after 
diversion.30 This has raised the hypothesis that lumi-
nal factors trigger the mucosal inflammation. The fall 
in levels of estrogens and progesterone at menopause 
could theoretically impair the epithelial barrier func-
tion, and the mucosa could be influenced to a greater 
extent by luminal factors, e.g. drugs. At the same time, 
the older the person, the more drugs are used, and the 
combination of different drugs may have a synergetic 
effect on the mucosa. As there was no difference in sex 
hormone influences between MC1 and MC2, it can be 
suggested that other factors are further involved in the 
pathophysiology  and  maintenance  of  inflammation. 
However, one limitation in this study is that we have 
not measured the sex hormone levels directly, only reg-
istered factors that indirectly affect sex hormone   levels. 
Another  limitation  is  the  small  cohort  in  the  study. 
Nevertheless, in light of the current knowledge on MC, 
a colonic, epithelial dysfunction seems more pertinent 
in the   pathophysiology of MC than   autoimmunity.31 
Intestinal ischemia, drugs, and environmental factors, 
such as smoking, may trigger mucosal changes which 
could represent an intestinal reaction to diverse irri-
tants rather than being a specific entity.12,32
There are several differences which affect sex hor-
mone levels between patients in our study and controls. 
These differences must be interpreted with caution 
as the controls are an external group. It is very dif-
ficult to recruit healthy volunteers to clinical   studies. 
The response rate of our control group was 41%, and 
  therefore it can be assumed that these subjects are 
healthier than those who did not agree to   participate. 
However, it is a strength for the first time to compare 
patients with MC with such a well-defined control 
group.10 Furthermore, the data concerning smoking, 
overweight, and level of education were similar to a 
study with 80% participation of the same   population.7 
The difference in OC consumption may be explained 
by  the  fact  that  the  external  control  group  was 
recruited two decades previously, and therefore may 
have not been exposed to OC to the same extent as 
the women born later. In the same way, the use of 
HRT  was  highest  during  the  nineties,  at  the  time 
when the control group was recruited. Later on, when 
the side effects were better known, the consumption 
of HRT had diminished.33 A higher use of OC ear-
lier in life should not be important as previous reports 
have shown that the increased risk of Crohn’s disease 
during OC treatment is reversed after cessation.18 In 
addition, it would have been useful to know the past 
use of HRT, not only the current use. However, as the 
response rate to this question was very low, we chose 
not to calculate with this parameter. Due to severe 
side effects of HRT, prevention of MC by prescrib-
ing HRT is not an option,33 and thus, of no clinical 
interest. The study is cross-sectional, and a prospec-
tive study is necessary to determine the time of initia-
tion of MC in relation to hormonal and environmental 
changes. Furthermore, few controls may also suffer 
from MC. However, as the prevalence of MC in the 
population is around 1–12 per 1000002 this could not 
affect the results.
In conclusion, there were no differences in expo-
sure to factors influencing sex hormones between 
CC and LC, or between MC1 and MC2, except-
ing that more patients with LC were nulliparous. 
Patients with MC reach menarche and menopause 
earlier and have been exposed to OC to a greater 
extent, and to a lesser extent to HRT, compared 
with  the  previously  recruited  controls.  Since  we 
found no differences in exposure to hormonal treat-
ments between patients with transient and persis-
tent MC, factors other than hormonal levels may 
affect the susceptibility to develop colonic, mucosal MC and hormonal factors
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inflammation to a greater extent, and luminal fac-
tors  should  be  further  examined  for  causality  in 
prospective studies.
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